a public good project by the
Synthesis
Company
of California

© 2026

Kentaro Takai | doi.page

0 works0 citations0 h-index

Kentaro Takai

Sumitomo Chemical (Japan)(JP)Sumitomo Dainippon Pharma (Japan)(JP)Gifu University(JP)

Publications by Year

Research Areas

Genetic Associations and Epidemiology, Bipolar Disorder and Treatment, Schizophrenia research and treatment, Neuroscience and Neuropharmacology Research, Receptor Mechanisms and Signaling

Most-Cited Works

→ The Auditory Steady-State Response: Electrophysiological Index for Sensory Processing Dysfunction in Psychiatric Disorders(2021)52 cited
→ Polygenic Risk Scores Differentiating Schizophrenia From Bipolar Disorder Are Associated With Premorbid Intelligence in Schizophrenia Patients and Healthy Subjects(2021)25 cited
→ Cognitive performances across individuals at high genetic risk for schizophrenia, high genetic risk for bipolar disorder, and low genetic risks: a combined polygenic risk score approach(2022)24 cited
→ Causal associations of intelligence with schizophrenia and bipolar disorder: A Mendelian randomization analysis(2021)22 cited
→ Discovery of NovelN-Substituted Oxindoles as Selective M₁and M₄Muscarinic Acetylcholine Receptors Partial Agonists(2013)22 cited
→ Intelligence decline across major depressive disorder, bipolar disorder, and schizophrenia(2021)20 cited

→ Discovery of dihydroquinazolinone derivatives as potent, selective, and CNS-penetrant M1 and M4 muscarinic acetylcholine receptors agonists(2015)19 cited

→ Three-dimensional rational approach to the discovery of potent substituted cyclopropyl urea soluble epoxide hydrolase inhibitors(2015)18 cited

→ Discovery of N-substituted 7-azaindoline derivatives as potent, orally available M1 and M4 muscarinic acetylcholine receptors selective agonists(2014)17 cited

→ Shared genetic basis between reproductive behaviors and anxiety-related disorders(2022)17 cited